Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries : issues in study design
| Autor: | Helen McShane, Adrian V. S. Hill, Patrick K. Owiafe, Helen A. Fletcher, Hannah B. Ibanga, Christian Lienhardt, Philip C. Hill, Roger H. Brookes, Richard A. Adegbola |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
Tuberculosis HIV Infections Vaccinia virus Mycobacterium tuberculosis chemistry.chemical_compound Immunocompromised Host Global health Medicine Humans Intensive care medicine Tuberculosis Vaccines Antigens Bacterial Clinical Trials as Topic Immunity Cellular biology business.industry biology.organism_classification medicine.disease Clinical trial Infectious Diseases Clinical research chemistry Immunology Inclusion and exclusion criteria Africa Vaccines Subunit Vaccinia business Tuberculosis vaccines Acyltransferases |
| Popis: | Tuberculosis remains a substantial global health problem despite effective drug treatments. The efficacy of BCG, the only available vaccine, is variable, especially in tuberculosis-endemic regions. Recent advances in the development of new vaccines against tuberculosis mean that the first of these are now entering into early clinical trials. A recombinant modified vaccinia virus Ankara expressing a major secreted antigen from Mycobacterium tuberculosis, antigen 85A, was the first new tuberculosis vaccine to enter into clinical trials in September 2002. This vaccine is known as MVA85A. In a series of phase I clinical trials in the UK, MVA85A had an excellent safety profile and was highly immunogenic. MVA85A was subsequently evaluated in a series of phase I trials in The Gambia, a tuberculosis-endemic area in west Africa. This vaccine is the only new subunit tuberculosis vaccine to enter into clinical trials in Africa to date. Here, we discuss some of the issues that were considered in the protocol design of these studies including recruitment, inclusion and exclusion criteria, reimbursement of study participants, and HIV testing. These issues are highly relevant to early clinical trials with all new tuberculosis vaccines in the developing world. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|